Our patent pending solutions are not costs: it serves the entirety of the drug life cycle market, offering unique and compelling benefits to key industry stakeholders.
PHARMACEUTICAL COMPANIES
HIE accelerates drug study completion, thereby maximizing post-approval, on-patent revenue for novel molecules.
CLINICAL RESEARCH ORGANIZATIONS
HIE facilitates the selection of patients eligible for clinical trials based on historical and real-time medical data, eliminating costly labor intensive field data collection relating to patient identification, selection and enrolment.
CLINICAL STUDY SITES
HIE enables sites to complete clinical trials faster and take on more research projects. It also reduces the need to hire and onboard costly in-house analysts to handle sensitive (personally identifiable) medical data, enabling more revenue.
PHYSICIANS AND PATIENTS
HIE increases access and awareness of innovative treatments and opportunities.
